DOCSLIB.ORG

The Link Between Cannabis Use, Immune System, and Viral Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Link Between Cannabis Use, Immune System, and Viral Infections viruses Review The Link between Cannabis Use, Immune System, and Viral Infections Sanjay B. Maggirwar 1,* and Jag H. Khalsa 1,2 1 Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20037, USA; [email protected] 2 Medical Consequences of Drug Abuse and Infections Branch, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20852, USA * Correspondence: [email protected] Abstract: Cannabis continues to be the most used drug in the world today. Research shows that cannabis use is associated with a wide range of adverse health consequences that may involve almost every physiological and biochemical system including respiratory/pulmonary complications such as chronic cough and emphysema, impairment of immune function, and increased risk of acquiring or transmitting viral infections such as HIV, HCV, and others. The review of published research shows that cannabis use may impair immune function in many instances and thereby exerts an impact on viral infections including human immune deficiency virus (HIV), hepatitis C infection (HCV), and human T-cell lymphotropic type I and II virus (HTLV-I/II). The need for more research is also highlighted in the areas of long-term effects of cannabis use on pulmonary/respiratory diseases, immune dysfunction and the risk of infection transmission, and the molecular/genetic basis of immune dysfunction in chronic cannabis users. Citation: Maggirwar, S.B.; Khalsa, Keywords: cannabis; marijuana; cannabinoids; immune system; infections; HIV; HCV; HTLV-I/II J.H. The Link between Cannabis Use, Immune System, and Viral Infections. Viruses 2021, 13, 1099. https:// doi.org/10.3390/v13061099 1. Introduction Today, marijuana (cannabis) is the most frequently used drug in the world, with over Academic Editors: Maria Cecilia 188 million users, or ~2.5% of the population that is 15–64 years of age [1]. In the United Garibaldi Marcondes and Marcus States, the percentage of people aged 12 or above who were past year marijuana users Kaul increased from 11.0 percent (or 25.8 million people) in 2002 to 17.5 percent (or 48.2 million people) in 2019 [2]. Approximately 2 to 3 million new users of marijuana are added each Received: 13 March 2021 year with about 1.1% becoming clinically dependent on it [3]. According to a recent annual Accepted: 3 June 2021 survey of high school students, known as Monitoring the Future (MTF), the total annual Published: 9 June 2021 marijuana prevalence rose by a significant 1.3% to 23.9% in 2017 with prevalence of 10%, 26%, and 37% in 8th, 10th and 12th graders, respectively, whereas daily marijuana use Publisher’s Note: MDPI stays neutral remained at 1%, 3%, and 6%, respectively [4]. In addition to problematic cannabis use, with regard to jurisdictional claims in an estimated 38 million people are living with human immune deficiency virus infection published maps and institutional affil- iations. (HIV [5]), 170 million people with hepatitis C virus (HCV [6]) infection, 10–20 million people with human T-lymphotropic virus type 1 (HTLV-1 [7]), and an estimated 161 million people have been infected with coronoavirus, SARS-Cov2 [8], in the world. Cannabis use is associated with a wide range of adverse economic, social, psychosocial and health consequences. The psychosocial consequences of marijuana use—such as dropping out of Copyright: © 2021 by the authors. school, poor school performance, and antisocial and other behaviors among youth—have Licensee MDPI, Basel, Switzerland. been the subjects of many reviews/publications. The health consequences of cannabis This article is an open access article use involve almost all physiological and biochemical systems including the immune, distributed under the terms and conditions of the Creative Commons cardiopulmonary/respiratory, hepatic, renal, endocrine, reproductive, and central nervous Attribution (CC BY) license (https:// systems, as well as genetics and general health [9–12]. This review presents current research creativecommons.org/licenses/by/ on the impact of cannabis use on the immune system which, in turn, may lead to increased 4.0/). Viruses 2021, 13, 1099. https://doi.org/10.3390/v13061099 https://www.mdpi.com/journal/viruses Viruses 2021, 13, 1099 2 of 13 risk of acquisition and transmission of viral infections including HIV, HCV, HTLV-I/II and SARS-CoV2. 2. Methods To prepare this review, we used the NIH PubMed database and Google Scholar, by using key words including cannabis, cannabinoids, tetrahydrocannabinol, THC, cannabid- iol, CBD, marijuana, immune system, viral infections, HIV, hepatitis C infection (HCV) and HTLV-I/II, and identified, retrieved and reviewed the papers published in the English language that are relevant to the topic of a link between cannabis, the immune system, and viral infections. 3. Cannabis and Immune System The cannabis sativa plant contains 560 chemicals, of which 104 are known as cannabi- noids [13]. The most studied cannabinoids are D9-tetrahydrocannabinol (THC), which produces the majority of its psychopharmacological and other effects through two cannabi- noid receptors, CB1 (localized mainly in the brain) and CB2 (localized mainly in the periphery), and cannabidiol (CBD), a non-psychoactive cannabinoid. The endogenous cannabinoids, known as the endocannabinoid system (ECS), consist of the endogenous lipid ligands N-arachidonoylethanolamine (anandamide; AEA) and 2-arachidonylglycerol (2-AG), their biosynthetic and degradative enzymes, and the CB1 and CB2 receptors that they activate. Endocannabinoids are present on immune cells such as monocytes, macrophages, basophils, lymphocytes, and dendritic cells and are enzymatically produced and released “on demand” in a similar fashion as the eicosanoids. Cannabidiol (CBD) and cannabinol (CBN) can alter the functional activities of the immune system [14]. Cannabis and its active cannabinoids act as immune-modulating agents, affecting T-cells, B-cells, mono- cytes, and microglia, causing an overall reduction in proinflammatory cytokine expression and an increase in anti-inflammatory cytokines. The role of ECS, CB1, CB2 and cannabi- noids in various physiological systems, including immunity and different pathologies, has been well discussed by Olah et al. [15], and Almogi-Hazan and Or [16]. More recently, De Silva et al.[17] suggested the role of neuroimmune activation and the subsequent in- crease in 18-kDa translocator protein (TSPO) levels in cannabis users. In a cross-sectional study of 24 long-term cannabis users and 27 non-cannabis using controls, by using PET scans, they measured the total distribution volume across regions of interest, stress and anxiety, peripheral measures of inflammatory cytokines and C-reactive protein levels, and found that cannabis users had higher total distribution volume, thus implicating it in the development of cannabis use disorder. Greater TSPO levels in the brain were found to be associated with stress and anxiety and with higher circulating C-reactive protein levels in cannabis users. Cannabidiol may serve as an immune suppressor via the suppression of activation of various immune cell types, the induction of apoptosis, and the promotion of regulatory cells, which, in turn, control other immune cell targets [18]. Although cannabis impairs cell-mediated and humoral immunity in animal models and decreases resistance to bac- terial and viral infections [19], there is no conclusive evidence to suggest that cannabis use impairs immune function, as measured by the number of T cell lymphocytes, B cell lymphocytes, macrophages, or levels of immunoglobulin in humans [20–22]. On the other hand, and more importantly, the chronic heavy smoking of cannabis weakens the immune system, leading to increased symptoms of chronic bronchitis, coughing, production of sputum, and wheezing [23–25], and impairs the pulmonary function, pulmonary respon- siveness, and bronchial cell characteristics in cannabis-only smokers. Tashkin et al. [26] further show that chronic cannabis smoking is associated with poorer lung function and greater abnormalities in the large airways of marijuana smokers than in nonsmokers, and a greater rate of decline in respiratory function among marijuana-only smokers than in tobacco-only smokers [27]. Both studies showed that long-term smoking of marijuana Viruses 2021, 13, 1099 3 of 13 increased bronchitis symptoms. Cannabis smokers also show significantly higher levels of cytologic components in their sputum when compared with sputum from tobacco smok- ers [28]. Thus, marijuana smoking may predispose individuals to pulmonary infection, especially among patients whose immune defenses are already compromised by HIV infection and/or cancer-related chemotherapy [26]. They reported that THC produced a concentration-dependent reduction in T cell proliferation and IFN-γ production via a CB2 receptor-dependent pathway, and at the level of gene expression, THC increased the expres- sion of Th1 cytokines (IFN-γ/IL-2) and reduced the expression of Th2 cytokines (IL-4/IL-5). However, they caution that the suppression of cell-mediated immunity by D9-THC may place marijuana smokers at risk for infection or cancer. Caiaffa and colleagues [29] reported almost four times higher incidence of bacterial pneumonia in HIV-seropositive subjects than among HIV-negative subjects, and smoking illicit drugs (marijuana, cocaine, or crack) had the strongest effect on the risk of bacterial pneumonia among HIV-seropositive
Load more

Recommended publications
  • Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
    6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder.
    [Show full text]
  • Cannabis (Sub)Culture, the Subcultural Repository, and Networked Mediation
    SIMULATED SESSIONS: CANNABIS (SUB)CULTURE, THE SUBCULTURAL REPOSITORY, AND NETWORKED MEDIATION Nathan J. Micinski A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS May 2014 Committee: Ellen Berry, Advisor Rob Sloane © 2014 Nathan Micinski All Rights Reserved iii ABSTRACT Ellen Berry, Advisor Subcultural theory is traditionally rooted in notions of social deviance or resistance. The criteria for determining who or what qualifies as subcultures, and the most effective ways to study them, are based on these assumptions. This project seeks to address these traditional modes of studying subcultures and discover ways in which their modification may lead to new understandings and ways of studying subcultures in the contemporary moment. This will be done by suggesting a change in the criteria of examining subcultures from that of deviance or resistance to identification with a collection of images, symbols, rituals, and narratives. The importance of this distinction is the ability to utilize the insights that studying subcultures can offer while avoiding the faults inherent in speaking for or at a subculture rather than with or from it. Beyond addressing theoretical concerns, this thesis aims to apply notions of subcultural theory to study the online community of Reddit, in particular, a subset known as r/trees–a virtual repository for those images, symbols, rituals, and narratives of cannabis subculture. R/trees illustrates the life and vibrancy of a unique subcultural entity, which to this point has evaded a cultural studies analysis. To that end, this project advocates for the importance of the cultural studies approach to analyzing cannabis subculture and further, to insert the findings of this study into that gap in the literature.
    [Show full text]
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
    [Show full text]
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands
    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
    [Show full text]
  • The Cannabinoid Receptor Agonist WIN 55,212-2 Attenuates the Effects Induced by Quinolinic Acid in the Rat Striatum
    Neuropharmacology 51 (2006) 1004e1012 www.elsevier.com/locate/neuropharm The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum A. Pintor a, M.T. Tebano a, A. Martire a, R. Grieco a, M. Galluzzo a, M.L. Scattoni b,A.Pe`zzola a, R. Coccurello c, F. Felici a, V. Cuomo d, D. Piomelli e, G. Calamandrei b, P. Popoli a,* a Department of Drug Research and Evaluation, Central Nervous System Pharmacology Division, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy b Department of Cell Biology and Neuroscience, Istituto Superiore di Sanita`, Viale Regina Elena, 299, 00161 Rome, Italy c Institute of Neuroscience, EBRI Foundation, Rome, Italy d Department of Pharmacology and General Physiology, University ‘‘La Sapienza’’, Rome, Italy e Department of Pharmacology and Center for Drug Discovery, University of California, Irvine, CA, USA Received 7 April 2006; received in revised form 15 May 2006; accepted 16 June 2006 Abstract The ability of CB1 receptors to regulate the release of glutamate in the striatum, together with the finding that, in experimental models of Huntington disease (HD), both endocannabinoid levels and CB1 receptor densities are reduced, has prompted the investigation on the neuropro- tective role of the cannabinoids in HD. Quinolinic acid (QA) is an excitotoxin that, when injected in the rat striatum reproduces many features of HD and that acts by stimulating glutamate outflow. The aim of the present study was to test the ability of the cannabinoid receptor agonist WIN 55,212-2 to prevent the effects induced by QA in the rat striatum.
    [Show full text]
  • Marijuana Myths and Facts: the Truth Behind 10 Popular Misperceptions
    MARIJUANA myths & FACTS The Truth Behind 10 Popular Misperceptions OFFICE OF NATIONAL DRUG CONTROL POLICY MARIJUANA myths & FACTS The Truth Behind 10 Popular Misperceptions OFFICE OF NATIONAL DRUG CONTROL POLICY TABLE OF CONTENTS Introduction.............................................................................. 1 Myth #1: Marijuana is harmless .......................................... 3 Myth #2: Marijuana is not addictive ................................... 7 Myth #3: Marijuana is not as harmful to your health as tobacco............................................................. 9 Myth #4: Marijuana makes you mellow............................. 10 Myth #5: Marijuana is used to treat cancer and other diseases...................................................... 11 Myth #6: Marijuana is not as popular as MDMA (Ecstasy) or other drugs among teens today...................... 13 Myth #7: If I buy marijuana, I’m not hurting anyone else......................................................... 14 Myth #8: My kids won’t be exposed to marijuana ............. 17 Myth #9: There’s not much parents can do to stop their kids from experimenting with marijuana ........... 19 Myth #10: The government sends otherwise innocent people to prison for casual marijuana use......... 21 Conclusion .............................................................................. 23 Glossary.................................................................................. 25 References ..............................................................................
    [Show full text]
  • Bill Analysis and Fiscal Impact Statement
    The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional Staff of the Committee on Agriculture BILL: SB 1766 INTRODUCER: Senator Powell SUBJECT: Sale of Hemp-derived Delta-8-tetrahydrocannabinol DATE: March 16, 2021 REVISED: ANALYST STAFF DIRECTOR REFERENCE ACTION 1. Becker Becker AG Pre-meeting 2. CJ 3. RC I. Summary: SB 1788 creates s. 581.218, F.S., to regulate the sale of hemp-derived delta-8- tetrahydrocannabinol (delta-8-THC) products. It provides definitions for certain terms relating to the sale of delta-8-THC products. The bill specifies that a sale of hemp-derived dela-8-THC products constitutes a delivery sale regardless of whether the person accepting the order for the delivery is located in Florida. A retailer who mails or ships any hemp-derived delta-8-THC products must: Obtain a certification from the consumer who is purchasing the product that he or she is 21 years of age or older; Include as part of the order’s shipping documents, in a clear and conspicuous manner, the following statement: “Hemp-derived Delta-8-Tetrahydrocannabinol Products: Florida law prohibits shipping to individuals under 21 years of age and requires the payment of all applicable taxes”; and Be in compliance with any labeling requirements, pursuant to Department of Agriculture and Consumer Services rule for the state hemp program. The bill outlines specific violations that are misdemeanors of the first degree. The bill is effective July 1, 2021 BILL: SB 1766 Page 2 II.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Cannabis Ordinance Revisions; Amending Berkeley Municipal Code Chapters 12.21, 12.22, 20.40, 23C.25, and Sub-Titles 23E and 23F
    Page 1 of 99 Office of the City Manager PUBLIC HEARING January 28, 2020 To: Honorable Mayor and Members of the City Council From: Dee Williams-Ridley, City Manager Submitted by: Timothy Burroughs, Director, Planning and Development Department Subject: Cannabis Ordinance Revisions; Amending Berkeley Municipal Code Chapters 12.21, 12.22, 20.40, 23C.25, and Sub-Titles 23E and 23F RECOMMENDATION Conduct a public hearing and upon conclusion, provide direction regarding proposed ordinance language alternatives and take the following action: Adopt the first reading of five ordinances to amend the Berkeley Municipal Code (BMC) Chapters 12.21, 12.22, 20.40, 23C.25, and Sub-Titles 23E and 23F which would: A. Allow new business types (Delivery-Only Retailers, Consumption Lounges); B. Allow Retailers to continue to operate as Microbusinesses; C. Clarify cannabis business operational standards and development standards, such as quotas and buffers, for Storefront Retailers; D. Allow more opportunities for Commercial Cultivation by expanding location options; and E. Protect the health of the general public and youth with additional advertising, signage and sales regulations. SUMMARY The proposed cannabis ordinances would revise definitions and establish operating standards for new and existing cannabis businesses in Berkeley, and include new regulations based on commission recommendations, Council direction, and Resolution 68,326-N.S., which established Berkeley as a sanctuary city for recreational cannabis use. The new ordinances would fully address new uses (Delivery-Only Retailers, Consumption Lounges and Retail Storefront Microbusinesses1), and modify development standards and signage requirements for existing uses. The proposed ordinances were reviewed by the Cannabis Commission (CC) and the Community Health Commission (CHC).
    [Show full text]
  • Synthetic Cannabis
    Global emergence of synthetic cannabinoids Source: https://www.unodc.org/LSS/SubstanceGroup/Details/ae45ce06-6d33-4f5f-916a- e873f07bde02 Source: UNODC questionnaire on NPS, 2012 Background The appearance of ‘herbal highs’ in the market is not a new phenomenon. Such products usually consisted of plant mixtures with little psychoactive effects. Since 2004, however, the composition of these herbal products seems to have substantially changed to include potent new psychoactive compounds known as synthetic cannabinoids. Research on the mechanism of cannabis activity dates back several decades when molecules with similar behaviour to Δ9-tetrahydrocannabinol (THC) were first examined. A synthetic analogue of THC , ‘HU-210’, was first synthesized in Israel in 1988[1]and is considered to have a potency of at least 100 times more than THC. Due to its similar chemical structure to THC, ‘HU-210’ is regarded as a ‘classical cannabinoid’ and has been found in synthetic cannabinoids sold in the United States and other countries. Non-classical cannabinoids include cyclohexylphenols or 3-arylcyclohexanols (‘CP’compounds). ‘CP’ compounds were developed as potential analgesics by a pharmaceutical company in the 1980s. Respondents to the UNODC questionnaire on NPS have reported the emergence of CP-47,497 and CP-47,497-C8 in numerous countries in all regions except Africa since 2009. Other structurally dissimilar varieties of synthetic cannabinoids unrelated to THC have also emerged on the market. These include aminoalkylindoles, such as naphthoylindoles (e.g. JWH-018), phenylacetylindoles (e.g. JWH-250), and benzoylindoles (e.g. AM-2233).[2] JWH-018, arguably the most widely known synthetic cannabinoid, belongs to the group of aminoalkylindoles and is considered to be three times as potent as THC.
    [Show full text]
  • The Cannabinoid WIN 55,212-2 Prevents Neuroendocrine Differentiation of Lncap Prostate Cancer Cells
    OPEN Prostate Cancer and Prostatic Diseases (2016) 19, 248–257 www.nature.com/pcan ORIGINAL ARTICLE The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells C Morell1, A Bort1, D Vara2, A Ramos-Torres1, N Rodríguez-Henche1 and I Díaz-Laviada1 BACKGROUND: Neuroendocrine (NE) differentiation represents a common feature of prostate cancer and is associated with accelerated disease progression and poor clinical outcome. Nowadays, there is no treatment for this aggressive form of prostate cancer. The aim of this study was to determine the influence of the cannabinoid WIN 55,212-2 (WIN, a non-selective cannabinoid CB1 and CB2 receptor agonist) on the NE differentiation of prostate cancer cells. METHODS: NE differentiation of prostate cancer LNCaP cells was induced by serum deprivation or by incubation with interleukin-6, for 6 days. Levels of NE markers and signaling proteins were determined by western blotting. Levels of cannabinoid receptors were determined by quantitative PCR. The involvement of signaling cascades was investigated by pharmacological inhibition and small interfering RNA. RESULTS: The differentiated LNCaP cells exhibited neurite outgrowth, and increased the expression of the typical NE markers neuron-specific enolase and βIII tubulin (βIII Tub). Treatment with 3 μM WIN inhibited NK differentiation of LNCaP cells. The cannabinoid WIN downregulated the PI3K/Akt/mTOR signaling pathway, resulting in NE differentiation inhibition. In addition, an activation of AMP-activated protein kinase (AMPK) was observed in WIN-treated cells, which correlated with a decrease in the NE markers expression. Our results also show that during NE differentiation the expression of cannabinoid receptors CB1 and CB2 dramatically decreases.
    [Show full text]